Preferred Label : Anti-CD137 Agonistic Monoclonal Antibody AGEN2373;
NCIt synonyms : Anti-CD137 Agonist Monoclonal Antibody AGEN2373; Anti-4-1BB Agonistic Monoclonal Antibody AGEN2373; Anti-CD137 Monoclonal Antibody AGEN2373;
NCIt definition : A conditionally-active, fully human immunoglobulin G1 (IgG1) agonistic monoclonal
antibody targeting the costimulatory receptor CD137 (4-1BB; tumor necrosis factor
receptor superfamily member 9; TNFRSF9), with potential immunostimulating and antineoplastic
activities. Upon administration, anti-CD137 agonistic monoclonal antibody AGEN2373
targets and binds to a non-ligand blocking epitope on CD137, thereby activating CD137
expressed on a variety of leukocyte subsets including activated T-lymphocytes and
natural killer (NK) cells. This enhances CD137-mediated signaling, induces cytotoxic
T-lymphocyte (CTL) proliferation, cytokine production and promotes a CTL-mediated
anti-tumor immune response as well as induces NK-mediated tumor cell killing and suppresses
the immunosuppressive activity of T-regulatory cells (Tregs). CD137, a surface glycoprotein
of the tumor necrosis factor receptor superfamily, is an inducible costimulatory receptor
that plays a key role in T-cell proliferation, survival and cytolytic activity. In
addition, as AGEN2373 engages with CD137 only in the presence of CD137 ligand and/or
Fc gamma receptor-expressing antigen-presenting cells (APCs), this agent may have
a decreased toxicity profile and improved tolerability compared to other agents that
activate CD137 signaling beyond the tumor site in humans.;
Molecule name : AGEN 2373; AGEN-2373;
NCI Metathesaurus CUI : CL972852;
Origin ID : C168522;
UMLS CUI : C5238912;
Semantic type(s)
- chemical_or_drug_affects_cell_type_or_tissue
- chemical_or_drug_has_mechanism_of_action
- chemical_or_drug_has_physiologic_effect
- concept_is_in_subset
- has_target
